[Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].
Identifieur interne : 000960 ( PubMed/Checkpoint ); précédent : 000959; suivant : 000961[Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].
Auteurs : S. Pinto [France] ; A. Ghio ; B. Teston ; F. VialletSource :
- Revue neurologique [ 0035-3787 ] ; 2010.
English descriptors
- KwdEn :
- Antiparkinson Agents (therapeutic use), Articulation Disorders (etiology), Articulation Disorders (therapy), Disease Progression, Dysarthria (etiology), Dysarthria (therapy), Dysphonia (etiology), Dysphonia (therapy), Humans, Parkinson Disease (complications), Parkinson Disease (drug therapy), Speech (physiology), Speech Intelligibility.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease.
- etiology : Articulation Disorders, Dysarthria, Dysphonia.
- physiology : Speech.
- therapy : Articulation Disorders, Dysarthria, Dysphonia.
- Disease Progression, Humans, Speech Intelligibility.
Abstract
Dysarthria refers to a collective name for a group of neurologic motor speech disorders, resulting from central and/or peripheral nervous system abnormalities. Speech alteration in Parkinson's disease, so-called hypokinetic dysarthria, presents with prosodic insufficiency, related to a monotony of pitch and intensity, a reduction of accentuation, variable speech rate and possible phoneme imprecision. In most cases, voice is harsh and breathy. This symptom can affect both voice and speech quality, as well as prosody and intelligibility. As a consequence, many patients complain about speech impairments, which affect their communication in daily living activities. Perceptual and instrumental assessments require different and numerous investigation methods, which use may help to further understand the specific dysarthria pathophysiology. This is of importance in order to adjust treatments for dysarthria; as a matter of fact, dopa-therapy, functional neurosurgery or even behavioural speech therapy have variable effects on voice and speech quality in Parkinson's disease.
DOI: 10.1016/j.neurol.2010.07.005
PubMed: 20800250
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:20800250Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].</title><author><name sortKey="Pinto, S" sort="Pinto, S" uniqKey="Pinto S" first="S" last="Pinto">S. Pinto</name><affiliation wicri:level="3"><nlm:affiliation>UMR 6057, Laboratoire Parole et Langage (LPL), CNRS, Université Aix-Marseille, BP 80975, 5 Avenue Pasteur, 13604 Aix-en-Provence Cedex 1, France. serge.pinto@lpl-aix.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 6057, Laboratoire Parole et Langage (LPL), CNRS, Université Aix-Marseille, BP 80975, 5 Avenue Pasteur, 13604 Aix-en-Provence Cedex 1</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Aix-en-Provence</settlement></placeName></affiliation></author><author><name sortKey="Ghio, A" sort="Ghio, A" uniqKey="Ghio A" first="A" last="Ghio">A. Ghio</name></author><author><name sortKey="Teston, B" sort="Teston, B" uniqKey="Teston B" first="B" last="Teston">B. Teston</name></author><author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F" last="Viallet">F. Viallet</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20800250</idno><idno type="pmid">20800250</idno><idno type="doi">10.1016/j.neurol.2010.07.005</idno><idno type="wicri:Area/PubMed/Corpus">000A50</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A50</idno><idno type="wicri:Area/PubMed/Curation">000A10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A10</idno><idno type="wicri:Area/PubMed/Checkpoint">000A10</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].</title><author><name sortKey="Pinto, S" sort="Pinto, S" uniqKey="Pinto S" first="S" last="Pinto">S. Pinto</name><affiliation wicri:level="3"><nlm:affiliation>UMR 6057, Laboratoire Parole et Langage (LPL), CNRS, Université Aix-Marseille, BP 80975, 5 Avenue Pasteur, 13604 Aix-en-Provence Cedex 1, France. serge.pinto@lpl-aix.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 6057, Laboratoire Parole et Langage (LPL), CNRS, Université Aix-Marseille, BP 80975, 5 Avenue Pasteur, 13604 Aix-en-Provence Cedex 1</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Aix-en-Provence</settlement></placeName></affiliation></author><author><name sortKey="Ghio, A" sort="Ghio, A" uniqKey="Ghio A" first="A" last="Ghio">A. Ghio</name></author><author><name sortKey="Teston, B" sort="Teston, B" uniqKey="Teston B" first="B" last="Teston">B. Teston</name></author><author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F" last="Viallet">F. Viallet</name></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term><term>Articulation Disorders (etiology)</term><term>Articulation Disorders (therapy)</term><term>Disease Progression</term><term>Dysarthria (etiology)</term><term>Dysarthria (therapy)</term><term>Dysphonia (etiology)</term><term>Dysphonia (therapy)</term><term>Humans</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Speech (physiology)</term><term>Speech Intelligibility</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Articulation Disorders</term><term>Dysarthria</term><term>Dysphonia</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Speech</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Articulation Disorders</term><term>Dysarthria</term><term>Dysphonia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Humans</term><term>Speech Intelligibility</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dysarthria refers to a collective name for a group of neurologic motor speech disorders, resulting from central and/or peripheral nervous system abnormalities. Speech alteration in Parkinson's disease, so-called hypokinetic dysarthria, presents with prosodic insufficiency, related to a monotony of pitch and intensity, a reduction of accentuation, variable speech rate and possible phoneme imprecision. In most cases, voice is harsh and breathy. This symptom can affect both voice and speech quality, as well as prosody and intelligibility. As a consequence, many patients complain about speech impairments, which affect their communication in daily living activities. Perceptual and instrumental assessments require different and numerous investigation methods, which use may help to further understand the specific dysarthria pathophysiology. This is of importance in order to adjust treatments for dysarthria; as a matter of fact, dopa-therapy, functional neurosurgery or even behavioural speech therapy have variable effects on voice and speech quality in Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20800250</PMID><DateCreated><Year>2010</Year><Month>09</Month><Day>27</Day></DateCreated><DateCompleted><Year>2010</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2010</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>166</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].</ArticleTitle><Pagination><MedlinePgn>800-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2010.07.005</ELocationID><Abstract><AbstractText>Dysarthria refers to a collective name for a group of neurologic motor speech disorders, resulting from central and/or peripheral nervous system abnormalities. Speech alteration in Parkinson's disease, so-called hypokinetic dysarthria, presents with prosodic insufficiency, related to a monotony of pitch and intensity, a reduction of accentuation, variable speech rate and possible phoneme imprecision. In most cases, voice is harsh and breathy. This symptom can affect both voice and speech quality, as well as prosody and intelligibility. As a consequence, many patients complain about speech impairments, which affect their communication in daily living activities. Perceptual and instrumental assessments require different and numerous investigation methods, which use may help to further understand the specific dysarthria pathophysiology. This is of importance in order to adjust treatments for dysarthria; as a matter of fact, dopa-therapy, functional neurosurgery or even behavioural speech therapy have variable effects on voice and speech quality in Parkinson's disease.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UMR 6057, Laboratoire Parole et Langage (LPL), CNRS, Université Aix-Marseille, BP 80975, 5 Avenue Pasteur, 13604 Aix-en-Provence Cedex 1, France. serge.pinto@lpl-aix.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghio</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Teston</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Viallet</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>La dysarthrie au cours de la maladie de Parkinson. Histoire naturelle de ses composantes: dysphonie, dysprosodie et dysarthrie.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001184" MajorTopicYN="N">Articulation Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004401" MajorTopicYN="N">Dysarthria</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055154" MajorTopicYN="N">Dysphonia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013065" MajorTopicYN="N">Speech Intelligibility</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>07</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>07</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20800250</ArticleId><ArticleId IdType="pii">S0035-3787(10)00331-0</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2010.07.005</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Aix-en-Provence</li></settlement></list><tree><noCountry><name sortKey="Ghio, A" sort="Ghio, A" uniqKey="Ghio A" first="A" last="Ghio">A. Ghio</name><name sortKey="Teston, B" sort="Teston, B" uniqKey="Teston B" first="B" last="Teston">B. Teston</name><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F" last="Viallet">F. Viallet</name></noCountry><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Pinto, S" sort="Pinto, S" uniqKey="Pinto S" first="S" last="Pinto">S. Pinto</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000960 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000960 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:20800250
|texte= [Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:20800250" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |